Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
Jaime S Rosa Duque, Xiwei Wang, Daniel Leung, Samuel M S Cheng, Carolyn A Cohen, Xiaofeng Mu, Asmaa Hachim, Yanmei Zhang, Sau Man Chan, Sara Chaothai, Kelvin K H Kwan, Karl C K Chan, John K C Li, Leo L H Luk, Leo C H Tsang, Wilfred H S Wong, Cheuk Hei Cheang, Timothy K Hung, Jennifer H Y Lam, Gilbert T Chua, Winnie W Y Tso, Patrick Ip, Masashi Mori, Niloufar Kavian, Wing Hang Leung, Sophie Valkenburg, Malik Peiris, Wenwei Tu, Yu Lung Lau, Jaime S Rosa Duque, Xiwei Wang, Daniel Leung, Samuel M S Cheng, Carolyn A Cohen, Xiaofeng Mu, Asmaa Hachim, Yanmei Zhang, Sau Man Chan, Sara Chaothai, Kelvin K H Kwan, Karl C K Chan, John K C Li, Leo L H Luk, Leo C H Tsang, Wilfred H S Wong, Cheuk Hei Cheang, Timothy K Hung, Jennifer H Y Lam, Gilbert T Chua, Winnie W Y Tso, Patrick Ip, Masashi Mori, Niloufar Kavian, Wing Hang Leung, Sophie Valkenburg, Malik Peiris, Wenwei Tu, Yu Lung Lau
Abstract
We present an interim analysis of a registered clinical study (NCT04800133) to establish immunobridging with various antibody and cellular immunity markers and to compare the immunogenicity and reactogenicity of 2-dose BNT162b2 and CoronaVac in healthy adolescents as primary objectives. One-dose BNT162b2, recommended in some localities for risk reduction of myocarditis, is also assessed. Antibodies and T cell immune responses are non-inferior or similar in adolescents receiving 2 doses of BNT162b2 (BB, N = 116) and CoronaVac (CC, N = 123) versus adults after 2 doses of the same vaccine (BB, N = 147; CC, N = 141) but not in adolescents after 1-dose BNT162b2 (B, N = 116). CC induces SARS-CoV-2 N and N C-terminal domain seropositivity in a higher proportion of adolescents than adults. Adverse reactions are mostly mild for both vaccines and more frequent for BNT162b2. We find higher S, neutralising, avidity and Fc receptor-binding antibody responses in adolescents receiving BB than CC, and a similar induction of strong S-specific T cells by the 2 vaccines, in addition to N- and M-specific T cells induced by CoronaVac but not BNT162b2, possibly implying differential durability and cross-variant protection by BNT162b2 and CoronaVac, the 2 most used SARS-CoV-2 vaccines worldwide. Our results support the use of both vaccines in adolescents.
Conflict of interest statement
The authors declare no competing interests.
© 2022. The Author(s).
Figures
References
- Johns Hopkins Coronavirus Resource Center. ().
- Smith C, et al. Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year. Nat. Med. 2021;28:185–192.
- Tso WWY, et al. Vulnerability and resilience in children during the COVID-19 pandemic. Eur. Child Adolesc. Psychiatry. 2020;31:161–176.
- Tso, W. W. Y. et al. Mental health & maltreatment risk of children with special educational needs during COVID-19. Child Abuse Neglect130, 105457 (2022).
- World Health Organization. Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing. , (2021).
- World Health Organization. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac. , (2021).
- Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;383:2603–2615.
- Tanriover MD, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398:213–222.
- Frenck RW, Jr., et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N. Engl. J. Med. 2021;385:239–250.
- Han B, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect. Dis. 2021;21:1645–1653.
- Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 2008;47:401–409.
- Khoury DS, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 2021;27:1205–1211.
- Bergwerk M, et al. Covid-19 breakthrough infections in vaccinated health care workers. N. Engl. J. Med. 2021;385:1474–1484.
- Gilbert PB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375:43–50.
- Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861–880.
- Rydyznski Moderbacher C, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996–1012 e1019.
- Earle KA, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39:4423–4428.
- Kalimuddin S, et al. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. Med (N. Y) 2021;2:682–688 e684.
- Yamin R, et al. Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature. 2021;599:465–470.
- Hachim A, et al. ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection. Nat. Immunol. 2020;21:1293–1301.
- Hachim, A. et al. SARS-CoV-2 accessory proteins reveal distinct serological signatures in children. Nat. Commun.13, 2951 (2022).
- Wu C, et al. Characterization of SARS-CoV-2 nucleocapsid protein reveals multiple functional consequences of the C-terminal domain. iScience. 2021;24:102681.
- Kalfaoglu B, Almeida-Santos J, Tye CA, Satou Y, Ono M. T-Cell hyperactivation and paralysis in severe COVID-19 infection revealed by single-cell analysis. Front Immunol. 2020;11:589380.
- Juno JA, et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat. Med. 2020;26:1428–1434.
- Koutsakos M, et al. Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Rep. Med. 2021;2:100208.
- Bucciol G, Tangye SG, Meyts I. Coronavirus disease 2019 in patients with inborn errors of immunity: lessons learned. Curr. Opin. Pediatr. 2021;33:648–656.
- Grifoni A, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181:1489–1501 e1415.
- Grifoni A, et al. SARS-CoV-2 human T cell epitopes: adaptive immune response against COVID-19. Cell Host Microbe. 2021;29:1076–1092.
- Swadling L, et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature. 2022;601:110–117.
- Kundu, R. et al. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nat. Commun.13, 80 (2022).
- Mok CKP, et al. Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. Respirology. 2021;4:301–310.
- Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin. Microbiol Infect. 2021;2:202–221.
- Wan EYF, et al. Bell’s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect. Dis. 2022;22:64–72.
- Chua, G. T. et al. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents following comirnaty vaccination. Clin. Infect. Dis.10.1093/cid/ciab989 (2021). Online ahead of print.
- Dagan N, Barda N, Balicer RD. Adverse effects after BNT162b2 vaccine and SARS-CoV-2 infection, according to age and sex. N. Engl. J. Med. 2021;385:2299.
- Scientific Committee on Emerging and Zoonotic Diseases and Scientific Committee on Vaccine Preventable Diseases, Centre for Health Protection, Department of Health, the Government of Hong Kong. Consensus Interim Recommendations on the Use of COVID-19 Vaccines in Hong Kong (As of 15 September 2021). .
- Mallapaty S. China’s COVID vaccines have been crucial — now immunity is waning. Nature. 2021;598:398–399.
- Lau EHY, et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat. Commun. 2021;12:63.
- Lau EH, et al. Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection. EClinicalMedicine. 2021;41:101174.
- Hodgson SH, et al. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect. Dis. 2021;21:e26–e35.
- Antia R, Halloran ME. Transition to endemicity: understanding COVID-19. Immunity. 2021;54:2172–2176.
- Buchan, S. A. et al. Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada. JAMA Netw Open5, e2218505 (2022).
- Mathew, D. et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science369, eabc8511 (2020).
- Burnet FM. Measles as an index of immunological function. Lancet. 1968;292:610–613.
- Coursaget P, et al. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J. Hepatol. 1994;21:250–254.
- Simons BC, et al. A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B virus (HBV) cellular immunity despite loss of antibody against HBV surface antigen. J. Infect. Dis. 2016;214:273–280.
- Jara A, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N. Engl. J. Med. 2021;385:875–884.
- Lopez Bernal J, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:n1088.
- GeurtsvanKessel, C. H. et al. Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients. Sci. Immunol. 7, eabo2202 (2022).
- Peng Y, et al. An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nat. Immunol. 2022;23:50–61.
- Keeton R, et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature. 2022;603:488–492.
- De Marco L, et al. Assessment of T-cell reactivity to the SARS-CoV-2 Omicron variant by immunized individuals. JAMA Netw. Open. 2022;5:e2210871.
- Liu J, et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature. 2022;603:493–496.
- Naranbhai V, et al. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell. 2022;185:1041–1051 e1046.
- Tarke A, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell. 2022;185:847–859.
- Heitmann, J. S. et al. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature601, 617–622 (2022).
- Dashdorj NJ, et al. Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia. Cell Host Microbe. 2021;29:1738–1743 e1734.
- Liu, X. et al. Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition. Proc Natl Acad Sci USA118, e2113401118 (2021).
- Chiu SS, Chan KH, Tu W, Lau YL, Peiris JS. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial. Vaccine. 2009;27:4834–4839.
- Chiu SS, Peiris JS, Chan KH, Wong WH, Lau YL. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics. 2007;119:1076–1082.
- Egunsola O, et al. Immunogenicity and safety of reduced-dose intradermal vs intramuscular influenza vaccines: a systematic review and meta-analysis. JAMA Netw. Open. 2021;4:e2035693.
- Lu, L. et al. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. Clin. Infect. Dis. ciab1041 (2021). Online ahead of print.
- Wilhelm, A. et al. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies. Preprint at 10.1101/2021.12.07.21267432 (2021).
- Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N. Engl. J. Med. 2021;386:494–496.
- UK Health Security Agency. COVID-19 vaccine surveillance report: Week 12. (2022).
- Bager, P. et al. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study. Lancet Infect Dis22, 967–976 (2022).
- Gram, M. A. et al. Vaccine effectiveness against SARS-CoV-2 infection and COVID-19-related hospitalization with the Alpha, Delta and Omicron SARS-CoV-2 variants: a nationwide Danish cohort study. Preprint at 10.1101/2022.04.20.22274061 (2022).
- McMenamin, M. E. et al. Vaccine effectiveness of two and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong (2022).
- Perera, R. A. et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill25, 2000421 (2020).
- Imamura T, Isozumi N, Higashimura Y, Ohki S, Mori M. Production of ORF8 protein from SARS-CoV-2 using an inducible virus-mediated expression system in suspension-cultured tobacco BY-2 cells. Plant Cell Rep. 2021;40:433–436.
- Sattler, A. et al. Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Invest131 e150175 (2021).
- Mateus J, et al. Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. Science. 2021;374:eabj9853.
- Liu X, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021;398:856–869.
- D’Agostino RB, Sr., Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Stat. Med. 2003;22:169–186.
- World Health Organization. Guidelines on clinical evaluation of vaccines: regulatory expectations. , (2017).
- Bikdeli B, et al. Noninferiority designed cardiovascular trials in highest-impact journals. Circulation. 2019;140:379–389.
Source: PubMed